Irene Griswold-Prenner

Irene Griswold-Prenner has an extensive work experience in the pharmaceutical industry. Irene is the Founder and CSO of Nitrase Therapeutics since September 2021, where they are leading the development of drugs for Parkinson's disease and other neurodegenerative diseases, heart disease, and cancer. Prior to that, they co-founded and served as the CEO/CSO of Nitrome Biosciences from June 2017 to September 2021, focusing on the development of disease-modifying drugs.

From 2014 to 2022, Irene was the Cofounder and CSO of Imago Pharmaceuticals, where they worked on the development of novel therapies for neurodegenerative, inflammatory, and autoimmune diseases.

Before joining Nitrase and Imago Pharmaceuticals, Irene worked as a Senior Director in Neurobiology at iPierian and True North Therapeutics from 2009 to 2014. Irene led the R&D Tau Program and managed the Neurobiology group, which focused on target identification/validation and drug development using iPSC technology.

Additionally, Irene was a Consultant at Datavision Consultants in 2009 and a Senior Scientist at Elan Pharmaceuticals from 1998 to 2009. Irene also gained experience as an SRA at UCLA from 1987 to 1989.

Irene Griswold-Prenner earned a Ph D in Pharmacology and Cellular Physiology from the University of Chicago, where they attended from 1989 to 1993. Prior to this, they obtained a BA in MCD Biology from the University of Colorado Boulder between 1983 and 1986. There is no specific information available regarding their education at the University of California, San Francisco.